Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the VANQUISH Phase 3 clinical program for their dual agonist VK2735. The program aims to evaluate the efficacy of VK2735 in treating obesity among adults, both with and without Type 2 Diabetes. VK2735, a dual agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous formulations. Previous positive results from the Phase 2 VENTURE study, which were announced in 2024, indicated that VK2735 achieved its primary and secondary endpoints. Patients receiving VK2735 showed statistically significant reductions in body weight compared to placebo, with weight loss maintained in follow-up visits. The study also reported encouraging safety and tolerability, with most adverse events being mild or moderate. Further results from ongoing studies, including a Phase 2 VENTURE-Oral Dosing study, are expected to be reported in the second half of this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.